



COLOMBIA

Number of new cases

117 620

Number of deaths

56 719

Number of prevalent cases (5-year)

303 656


Statistics at a glance, 2022

	Males	Females	Both sexes
Population	25 286 674	26 226 092	51 512 766
Incidence*			
Number of new cancer cases	56 224	61 396	117 620
Age-standardized incidence rate	183.3	175.3	177.6
Risk of developing cancer before the age of 75 years (cum. risk %)	18.9	17.2	17.9
Top 3 leading cancers (ranked by cases)**	Prostate Colorectum Stomach	Breast Colorectum Cervix uteri	Breast Prostate Colorectum
Mortality*			
Number of cancer deaths	27 816	28 903	56 719
Age-standardized mortality rate	87.6	76.9	81.4
Risk of dying from cancer before the age of 75 years (cum. risk %)	8.8	7.9	8.3
Top 3 leading cancers (ranked by deaths)**	Prostate Stomach Lung	Breast Colorectum Stomach	Stomach Lung Colorectum
Prevalence*			
5-year prevalent cases	133 132	170 524	303 656



Top 5 most frequent cancers**


Males



Rank	Cancer site	Number of cases	Percent
1st	Prostate	16 479	29.3%
2nd	Colorectum	5 455	9.7%
3rd	Stomach	5 437	9.7%
4th	Lung	4 178	7.4%
5th	NHL	2 229	4.0%
-	Others	22 446	39.9%

Number of new cases in 2022, males, all ages


Females



Rank	Cancer site	Number of cases	Percent
1st	Breast	17 018	27.7%
2nd	Colorectum	5 708	9.3%
3rd	Cervix uteri	4 570	7.4%
4th	Thyroid	4 029	6.6%
5th	Stomach	3 501	5.7%
-	Others	26 570	43.3%

Number of new cases in 2022, females, all ages

Both sexes



Rank	Cancer site	Number of cases	Percent
1st	Breast	17 018	14.5%
2nd	Prostate	16 479	14.0%
3rd	Colorectum	11 163	9.5%
4th	Stomach	8 938	7.6%
5th	Lung	7 196	6.1%
-	Others	56 826	48.3%

Number of new cases in 2022, both sexes, all ages

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Breast	17 018	1	14.5	5.4	4 752	4	8.4	1.4	54 604	208.2
Prostate	16 479	2	14.0	6.4	4 304	5	7.6	0.99	39 839	157.6
Colorectum	11 163	3	9.5	1.9	5 640	3	9.9	0.85	31 549	61.3
Stomach	8 938	4	7.6	1.4	6 901	1	12.2	1.1	12 769	24.8
Lung	7 196	5	6.1	1.2	6 124	2	10.8	0.99	8 936	17.4
Thyroid	4 885	6	4.2	0.84	517	20	0.91	0.08	16 797	32.6
Cervix uteri	4 570	7	3.9	1.4	2 435	7	4.3	0.74	14 376	54.8
NHL	3 864	8	3.3	0.66	1 873	10	3.3	0.31	12 005	23.3
Leukaemia	3 399	9	2.9	0.51	2 428	8	4.3	0.36	10 181	19.8
Corpus uteri	3 045	10	2.6	1.1	662	17	1.2	0.22	10 825	41.3
Pancreas	2 812	11	2.4	0.45	2 573	6	4.5	0.41	2 624	5.1
Liver	2 591	12	2.2	0.41	2 396	9	4.2	0.37	2 997	5.8
Kidney	2 374	13	2.0	0.42	829	15	1.5	0.14	7 122	13.8
Ovary	2 253	14	1.9	0.75	1 445	12	2.5	0.47	6 503	24.8
Bladder	2 035	15	1.7	0.32	805	16	1.4	0.10	5 874	11.4
Brain CNS	1 969	16	1.7	0.32	1 636	11	2.9	0.27	7 315	14.2
Melanoma	1 773	17	1.5	0.28	463	21	0.82	0.07	5 880	11.4
Multiple myeloma	1 362	18	1.2	0.26	1 039	13	1.8	0.19	3 843	7.5
Testis	1 266	19	1.1	0.35	184	25	0.32	0.05	4 912	19.4
Oesophagus	1 019	20	0.87	0.15	924	14	1.6	0.13	1 258	2.4
Larynx	954	21	0.81	0.17	536	18	0.95	0.08	2 812	5.5
Lip, oral cavity	890	22	0.76	0.14	413	22	0.73	0.06	2 555	5.0
Hodgkin lymphoma	695	23	0.59	0.11	230	23	0.41	0.04	2 348	4.6
Gallbladder	669	24	0.57	0.11	519	19	0.92	0.09	896	1.7
Oropharynx	569	25	0.48	0.09	207	24	0.37	0.03	1 607	3.1
Penis	513	26	0.44	0.16	154	26	0.27	0.05	1 450	5.7
Salivary glands	457	27	0.39	0.07	130	27	0.23	0.02	1 371	2.7
Kaposi sarcoma	453	28	0.39	0.07	58	31	0.10	0.01	1 262	2.5
Vulva	394	29	0.34	0.11	114	29	0.20	0.02	1 212	4.6
Vagina	183	30	0.16	0.06	57	32	0.10	0.01	476	1.8
Nasopharynx	176	31	0.15	0.03	90	30	0.16	0.01	525	1.0
Mesothelioma	139	32	0.12	0.03	129	28	0.23	0.02	203	0.39
All cancers	117 620	-	-	17.9	56 719	-	-	8.3	303 656	-
All cancers excl. NMSC	114 573	-	-	17.6	56 048	-	-	8.3	294 336	-

Data source and methods

Incidence

Country-specific data source: No data
Method: Estimated from national mortality estimates by modelling, using mortality:incidence ratios derived from survival estimation

[Click here to see detailed data source and methods](#)



Mortality

Country-specific data source: National (WHO)
Method: National rates projected to 2022

[Click here to see detailed data source and methods](#)

Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



* includes non-melanoma skin cancer (NMSC)

** NMSC included in other cancers

Age standardization using world population ([see link](#))

References

Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021 Feb 4. doi:10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. *Int J Cancer*. 2021 Apr 5. doi:10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

